178 related articles for article (PubMed ID: 26208525)
21. Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.
Eritja N; Domingo M; Dosil MA; Mirantes C; Santacana M; Valls J; Llombart-Cussac A; Matias-Guiu X; Dolcet X
Mol Cancer Ther; 2014 Apr; 13(4):776-87. PubMed ID: 24448819
[TBL] [Abstract][Full Text] [Related]
22. Antitumoral effects of dovitinib in triple-negative breast cancer are synergized by calcitriol in vivo and in vitro.
García-Quiroz J; Cárdenas-Ochoa N; García-Becerra R; Morales-Guadarrama G; Méndez-Pérez EA; Santos-Cuevas C; Ramírez-Nava GJ; Segovia-Mendoza M; Prado-García H; Avila E; Larrea F; Díaz L
J Steroid Biochem Mol Biol; 2021 Nov; 214():105979. PubMed ID: 34438041
[TBL] [Abstract][Full Text] [Related]
23.
Das A; Martinez Santos JL; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
Cancer Invest; 2020 Jul; 38(6):349-355. PubMed ID: 32441531
[No Abstract] [Full Text] [Related]
24. Dovitinib induces mitotic defects and activates the G2 DNA damage checkpoint.
Man WY; Mak JP; Poon RY
J Cell Mol Med; 2014 Jan; 18(1):143-55. PubMed ID: 24238094
[TBL] [Abstract][Full Text] [Related]
25. RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib.
Mukhopadhyay S; Pennell NA; Ali SM; Ross JS; Ma PC; Velcheti V
J Thorac Oncol; 2014 Nov; 9(11):1714-9. PubMed ID: 25436805
[TBL] [Abstract][Full Text] [Related]
26. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.
Fujihara S; Morishita A; Ogawa K; Tadokoro T; Chiyo T; Kato K; Kobara H; Mori H; Iwama H; Masaki T
Oncotarget; 2017 Jan; 8(5):8536-8549. PubMed ID: 28052030
[TBL] [Abstract][Full Text] [Related]
27. Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
Kim JO; Shin JY; Kim MY; Son KH; Jung CK; Kim TJ; Kim SY; Park JK; Sung SW; Bae SJ; Min HJ; Kang JH
Surg Oncol; 2018 Mar; 27(1):106-113. PubMed ID: 29549897
[TBL] [Abstract][Full Text] [Related]
28. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
Matsubara D; Kanai Y; Ishikawa S; Ohara S; Yoshimoto T; Sakatani T; Oguni S; Tamura T; Kataoka H; Endo S; Murakami Y; Aburatani H; Fukayama M; Niki T
J Thorac Oncol; 2012 Dec; 7(12):1872-1876. PubMed ID: 23154560
[TBL] [Abstract][Full Text] [Related]
29. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
Lai YH; Chen MH; Lin SY; Lin SY; Wong YH; Yu SL; Chen HW; Yang CH; Chang GC; Chen JJ
Oncotarget; 2015 Sep; 6(28):26252-65. PubMed ID: 26312766
[TBL] [Abstract][Full Text] [Related]
30. Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src.
Diao Y; Ma X; Min W; Lin S; Kang H; Dai Z; Wang X; Zhao Y
Cancer Lett; 2016 Aug; 379(1):12-23. PubMed ID: 27195913
[TBL] [Abstract][Full Text] [Related]
31. Pterostilbene exerts antitumor activity via the Notch1 signaling pathway in human lung adenocarcinoma cells.
Yang Y; Yan X; Duan W; Yan J; Yi W; Liang Z; Wang N; Li Y; Chen W; Yu S; Jin Z; Yi D
PLoS One; 2013; 8(5):e62652. PubMed ID: 23671619
[TBL] [Abstract][Full Text] [Related]
32. Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.
Zhang L; Moccia M; Briggs DC; Bharate JB; Lakkaniga NR; Knowles P; Yan W; Tran P; Kharbanda A; Wang X; Leung YK; Frett B; Santoro M; McDonald NQ; Carlomagno F; Li HY
J Med Chem; 2022 Jan; 65(2):1536-1551. PubMed ID: 35081714
[TBL] [Abstract][Full Text] [Related]
33. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.
Zhang SR; Xu YS; Jin E; Zhu LC; Xia B; Chen XF; Li FZ; Ma SL
Acta Pharmacol Sin; 2017 Jan; 38(1):100-109. PubMed ID: 27840409
[TBL] [Abstract][Full Text] [Related]
34. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
35. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.
Hasinoff BB; Wu X; Nitiss JL; Kanagasabai R; Yalowich JC
Biochem Pharmacol; 2012 Dec; 84(12):1617-26. PubMed ID: 23041231
[TBL] [Abstract][Full Text] [Related]
36. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
Plenker D; Riedel M; Brägelmann J; Dammert MA; Chauhan R; Knowles PP; Lorenz C; Keul M; Bührmann M; Pagel O; Tischler V; Scheel AH; Schütte D; Song Y; Stark J; Mrugalla F; Alber Y; Richters A; Engel J; Leenders F; Heuckmann JM; Wolf J; Diebold J; Pall G; Peifer M; Aerts M; Gevaert K; Zahedi RP; Buettner R; Shokat KM; McDonald NQ; Kast SM; Gautschi O; Thomas RK; Sos ML
Sci Transl Med; 2017 Jun; 9(394):. PubMed ID: 28615362
[TBL] [Abstract][Full Text] [Related]
37. Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models.
Crawford K; Bontrager E; Schwarz MA; Chaturvedi A; Lee DD; Md Sazzad H; von Holzen U; Zhang C; Schwarz RE; Awasthi N
Cancer Biol Ther; 2021 Dec; 22(10-12):619-629. PubMed ID: 34882068
[TBL] [Abstract][Full Text] [Related]
38. The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G
Jiang Y; Peng X; Ji Y; Dai Y; Fang Y; Xiong B; Ren W; Hu Y; Chen Y; Ai J
Mol Cancer Ther; 2021 Nov; 20(11):2198-2206. PubMed ID: 34518294
[TBL] [Abstract][Full Text] [Related]
39. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
Frett B; Carlomagno F; Moccia ML; Brescia A; Federico G; De Falco V; Admire B; Chen Z; Qi W; Santoro M; Li HY
Angew Chem Int Ed Engl; 2015 Jul; 54(30):8717-21. PubMed ID: 26126987
[TBL] [Abstract][Full Text] [Related]
40. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]